Home » Topics » BioWorld Science

BioWorld Science
RSS

Pfizer presents PF-06855800, a novel PRMT5 inhibitor for cancer

March 20, 2018

Cidara reports phase II topline data on antifungal rezafungin

March 20, 2018

FDA grants fast track designation to nintedanib for SSc-ILD

March 20, 2018

FDA grants orphan drug designation to Cellectar's CLR-131 for neuroblastoma

March 20, 2018

Knight Therapeutics gains rights to commercialize tenapanor in Canada

March 20, 2018

FDA grants QIDP designation to APX-001 for treatment of cryptococcosis

March 20, 2018

Serum amyloid A-1 protein useful for diagnosing spontaneous bacterial peritonitis

March 20, 2018

Merck Sharp & Dohme initiates phase III trial of gefapixant in adults with chronic cough

March 20, 2018

New phase I trial studies safety of GamEMab in healthy volunteers for emergency prevention of Ebola

March 20, 2018

NeuPharma identifies novel BTK and EGFR inhibitors

March 20, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Nov. 12, 2025.
Could restricting diversity efforts stall women’s health research?
BioWorld
Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...
Alkermes’ alixorexton hits endpoints in narcolepsy phase II
BioWorld
Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...
Pazdur ‘optimal fit’ to lead FDA’s CDER
BioWorld
In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...